Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1997-12-24
pubmed:abstractText
We isolated human intercrine reduced in hepatomas (hIRH) as a mRNA whose expression was reduced in differential displays from human hepatocellular carcinoma. hIRH is equivalent to the alpha-chemokine SDF-1alpha/PBSF. We have previously demonstrated on Northern blot analysis that although hIRH mRNA expression is common in human normal tissues, it is absent from pre-malignant colonic adenomas and from 27 human malignant cell lines. However, there are no reports on the mRNA status of hIRH in other human cancers. The present study was designed to investigate semi-quantitatively the expression of hIRH/SDF-1alpha mRNA in hepatocellular carcinoma and digestive tract cancers by reverse transcription-polymerase chain reaction (RT-PCR). The expression of hIRH/SDF-1alpha in the majority of cancer tissues analyzed was markedly reduced compared with that in adjacent non-cancer tissue. RT-PCR was more sensitive than Northern blots in the detection of hIRH mRNA. The average (mean +/- SE) tumor/normal (T/N) ratio determined by RT-PCR was 0.40 +/- 0.07 in 10 pairs of hepatoma, 0.38 +/- 0.09 in 14 pairs of colon cancers, 0.43 +/- 0.07 in 10 pairs of esophageal cancers and 0.70 +/- 0.09 in 26 pairs of gastric cancers. As a control, the mean G3PDH T/N ratio was 1.16 +/- 0.06. The distribution of T/N ratios was significantly different between gastric cancer and the other cancers, but there was no correlation between hIRH/SDF-1alpha expression and clinicopathological characteristics in gastric cancer. Our findings demonstrate that hIRH/SDF-1alpha expression is reduced in the majority of gastrointestinal tumors.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0020-7136
pubmed:author
pubmed:issnType
Print
pubmed:day
27
pubmed:volume
73
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
656-62
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:9398042-Adult, pubmed-meshheading:9398042-Aged, pubmed-meshheading:9398042-Blotting, Northern, pubmed-meshheading:9398042-Carcinoma, Hepatocellular, pubmed-meshheading:9398042-Chemokine CXCL12, pubmed-meshheading:9398042-Chemokines, pubmed-meshheading:9398042-Chemokines, CXC, pubmed-meshheading:9398042-Cytokines, pubmed-meshheading:9398042-DNA, Neoplasm, pubmed-meshheading:9398042-DNA Primers, pubmed-meshheading:9398042-Digestive System Neoplasms, pubmed-meshheading:9398042-Electrophoresis, Agar Gel, pubmed-meshheading:9398042-Female, pubmed-meshheading:9398042-Gene Expression Regulation, Neoplastic, pubmed-meshheading:9398042-Humans, pubmed-meshheading:9398042-Liver Neoplasms, pubmed-meshheading:9398042-Male, pubmed-meshheading:9398042-Middle Aged, pubmed-meshheading:9398042-Polymerase Chain Reaction, pubmed-meshheading:9398042-RNA, Messenger
pubmed:year
1997
pubmed:articleTitle
Reduced expression of the CXC chemokine hIRH/SDF-1alpha mRNA in hepatoma and digestive tract cancer.
pubmed:affiliation
Department of Medicine, University of Massachusetts Medical Center, Worcester 01655-0310, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't